CureWize translates biomedical research into clinical practice for improving the treatment of young cancer patients.
Curewize Ltd. is an expert in developing and commercializing biomarker assays. Our lead product, is ProALL, a prognostic test developed at Schneider Children’s’ Medical Center for tailoring and monitoring leukemia patients' treatment. ProALL is markedly better, faster and less costly than the current routinely used tests. The FDA acknowledged the need for improved prognostic assays such as ProALL. ProALL’s natural home market is global.